Analyst report (real analyst) are showing $2.6M of revenue for 2022 and $2.4M for 2023. Yup, going down!

The last 2 quarters weren't good either as they surprised the analysts (real analyst) with lower numbers.

No wonder why BlackRock who was one of the largest institutions had enough.

Market Cap of $56M and revenue potentially $2.6M

That's a 23 forward multiple of revenues

Way too high in my opinion. x2 would be about right given how long it will take and how much it will cost to get these drugs to market. So x2 would be a $5M company.

I'll watch this stock over the next 8 years and see if revenues ever catch up to what the CEO makes, which right now is 2x revenue.